Pedrosa Pedro, Vinhas Raquel, Fernandes Alexandra, Baptista Pedro V
UCIBIO, Department of Life Sciences, Faculdade de Ciências e Tecnologia, Campus Caparica, 2829-516 Caparica, Portugal.
Nanomaterials (Basel). 2015 Nov 3;5(4):1853-1879. doi: 10.3390/nano5041853.
Nanoparticles have been making their way in biomedical applications and personalized medicine, allowing for the coupling of diagnostics and therapeutics into a single nanomaterial-nanotheranostics. Gold nanoparticles, in particular, have unique features that make them excellent nanomaterials for theranostics, enabling the integration of targeting, imaging and therapeutics in a single platform, with proven applicability in the management of heterogeneous diseases, such as cancer. In this review, we focus on gold nanoparticle-based theranostics at the lab bench, through pre-clinical and clinical stages. With few products facing clinical trials, much remains to be done to effectively assess the real benefits of nanotheranostics at the clinical level. Hence, we also discuss the efforts currently being made to translate nanotheranostics into the market, as well as their commercial impact.
纳米颗粒已在生物医学应用和个性化医疗领域崭露头角，使诊断与治疗能够结合在单一的纳米材料——纳米诊疗剂中。特别是金纳米颗粒，具有独特的特性，使其成为用于诊疗的优异纳米材料，能够在单一平台上实现靶向、成像和治疗的整合，在诸如癌症等异质性疾病的管理中已证明具有适用性。在本综述中，我们关注基于金纳米颗粒的诊疗技术，涵盖从实验室阶段到临床前及临床阶段的情况。由于面临临床试验的产品寥寥无几，要在临床层面有效评估纳米诊疗的实际益处仍有许多工作要做。因此，我们还将讨论目前为将纳米诊疗技术推向市场所做的努力及其商业影响。
